TNF-Alpha Inhibitors Will Continue To Dominate First- And Second-Line Biologic Therapy For The Treatment Of Rheumatoid Arthritis Through 2011

Decision Resources, one of the worlds leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the U